Printer Friendly

NEORX PROMOTES ROBERT LITTAUER TO SENIOR VICE PRESIDENT

 SEATTLE, April 16 /PRNewswire/ -- NeoRx Corporation (NASDAQ: NERX) today announced that it has promoted Robert M. Littauer, M.B.A., C.P.A., to senior vice president, chief financial officer and treasurer.
 Mr. Littauer received his M.B.A. and bachelor of science in engineering from Cornell University. He began his career in public accounting in the Boston office of Arthur Andersen & Co. and then became corporate controller of Instrumentation Laboratory, Inc., a publicly- held international manufacturer of scientific and analytical instrumentation subsequently sold to Allied-Signal, Inc. Immediately prior to joining NeoRx Corporation in 1987, he was vice president- finance and treasurer of Concept, Inc., a publicly-traded manufacturer of medical surgical products that was sold to Bristol-Myers Squibb. During his tenure at Concept, he co-managed the acquisition of an arthroscopy company, the divestiture of the company's consumer products division and various financings.
 Mr. Littauer joined NeoRx Corporation in June 1987. He managed the company's financings including its IPO in 1988, convertible securities offering and its 1991 $10 million private placement. In addition to finance and accounting, he has managed the company's investor relations and information systems functions, and more recently, assumed responsibility for manufacturing.
 "Bob Littauer's arrival at NeoRx marked the beginning of sophisticated cost tracking and control systems that were essential to implement the corporate reorganization designed to make more productive use of our resources," said Paul Abram, NeoRx's president and CEO. "In addition to raising over $55 million, he reduced the company's debt from a peak of $28 million to just $1 million, and has kept expenses steady for several years even as our product portfolio has expanded. He has been a key contributor to NeoRx's resurgence, and we are very pleased that he has accepted additional responsibilities as we move forward to execute our strategic plan."
 NeoRx Corporation develops targeted biopharmaceutical products that detect and treat human illnesses with a primary focus on cancer. The company has three cancer therapy trials in progress, has filed for marketing approval with the FDA its OncoTrac(R) Small Cell Lung Cancer Imaging Product and has completed a phase III trial for a non-small cell lung cancer imaging agent. Targeted biopharmaceuticals to treat cancer and restenosis after angioplasty are in pre-clinical testing.
 -0- 4/16/93
 /CONTACT: Robert M. Littauer, senior vice president and CFO of NeoRx, 206-286-2519; or Bonnie K. Sterling of Noonan/Russo Communications, 212-979-9180, for NeoRx/
 (NERX)


CO: NeoRx Corporation ST: Washington IN: MTC SU: PER

GK-SH -- NY017 -- 6654 04/16/93 10:10 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 16, 1993
Words:417
Previous Article:DRESSER NAMES PAUL BRYANT VICE PRESIDENT
Next Article:NEORX PROMOTES JEFFREY MILLER TO SENIOR VICE PRESIDENT
Topics:


Related Articles
NEORX ACQUIRES PRE-TARGETING TECHNOLOGY FROM STANFORD UNIVERSITY
NEORX SIGNS SECOND COLLABORATIVE RESEARCH AGREEMENT WITH GENENTECH
NEORX DECLARES DIVIDEND
NEORX APPOINTS JOHN RENO AS VICE PRESIDENT, RESEARCH & DEVELOPMENT
NEORX APPOINTS ROBERT SCHROFF AS VICE PRESIDENT & GENERAL MANGER, CARDIOVASCULAR PRODUCTS
NEORX REPORTS FIRST QUARTER 1993 RESULTS
NEORX PROMOTES JEFFREY MILLER TO SENIOR VICE PRESIDENT
NEORX REPORTS SECOND QUARTER 1993 RESULTS
NEORX REPORTS 1994 FIRST QUARTER RESULTS

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters